The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.7, 2012-07, pp. : 901-904

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Elvitegravir: a once-daily inhibitor of HIV-1 integrase

By Wills Todd Vega Vivian

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 395-401

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic and bioequivalence evaluation of single‐tablet and separate‐tablet regimens for once‐daily cobicistat‐boosted elvitegravir in healthy Japanese male subjects: A randomized, two‐way crossover study

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 3, 2015-03 ,pp. : 218-225

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of HIV infection with once-daily regimens

By Permpalung Nitipong Putcharoen Opass Avihingsanon Anchalee Ruxrungtham Kiat

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2301-2317

Informa Healthcare

Access to resources Recommend Favorite

Triple therapy including once-daily emtricitabine effective in HIV

Inpharma, Vol. 1, Iss. 1278, 2001-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection

By Molina Jean-Michel

Drugs, Vol. 68, Iss. 5, 2008-01 ,pp. : 567-578

Adis International

Access to resources Recommend Favorite